{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:33Z","timestamp":1790742993902,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant genetic disorder. It is the most fatal among all types of EDS. In addition to typical EDS characteristics, vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the <jats:italic toggle=\"yes\">COL3A1<\/jats:italic> gene, which encodes type III collagen. Type III collagen is a major component of humans\u2019 vascular walls. The management of this disease is possible; however, there is no cure as of present. Recently, discoveries with potential impact on the management of vEDS have been elucidated. Mice with vEDS traits treated with a beta-blocker celiprolol showed significant improvements in their thoracic aorta biomechanical strength. Moreover, it has been demonstrated that the specifically designed small interference RNAs (siRNA) can effectively silence the pathogenic variant allele. To enhance the normal allele expression, an intracellularly expressed lysyl oxidase is shown to regulate the transcription rate of the <jats:italic toggle=\"yes\">COL3A1<\/jats:italic> promoter. Similarly, an embryonic homeobox transcription factor Nanog upregulates the wild-type <jats:italic toggle=\"yes\">COL3A1<\/jats:italic> expression through activation of the transforming growth factor-beta pathway, which increases type III collagen synthesis. Despite numerous advancements, more studies are to be performed to incorporate these discoveries into clinical settings, and eventually, more personalized treatments can be created.<\/jats:p>","DOI":"10.1097\/crd.0000000000000419","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T02:00:23Z","timestamp":1632535223000},"page":"308-313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Vascular Ehlers-Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches"],"prefix":"10.1097","volume":"30","author":[{"given":"Chanika","family":"Assavarittirong","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Yuen","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu Vinh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Jagiellonian University, Krak\u00f3w, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Mostowska","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.gene.2019.05.003","article-title":"Type III collagen (COL3A1): gene and protein structure, tissue distribution, and associated diseases.","volume":"707","author":"Kuivaniemi","year":"2019","journal-title":"Gene"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1538574417692114","article-title":"A New COL3A1 mutation in Ehlers-Danlos syndrome vascular type with different phenotypes in the same family.","volume":"51","author":"Cortini","year":"2017","journal-title":"Vasc Endovascular Surg"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"e0191220","DOI":"10.1371\/journal.pone.0191220","article-title":"Transcriptome analysis of skin fibroblasts with dominant negative COL3A1 mutations provides molecular insights into the etiopathology of vascular Ehlers-Danlos syndrome.","volume":"13","author":"Chiarelli","year":"2018","journal-title":"PLoS One"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jvs.2019.04.487","article-title":"A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis.","volume":"71","author":"Shalhub","year":"2020","journal-title":"J Vasc Surg"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamafacial.2017.0793","article-title":"Characteristics, diagnosis, and management of ehlers-danlos syndromes: a review.","volume":"20","author":"Joseph","year":"2018","journal-title":"JAMA Facial Plast Surg"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/CRD.0b013e3182342316","article-title":"Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications.","volume":"20","author":"Beridze","year":"2012","journal-title":"Cardiol Rev"},{"key":"R9-20250619","first-page":"457","article-title":"Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome.","volume":"116","author":"Dubacher","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/ejhg.2015.32","article-title":"The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome.","volume":"23","author":"Frank","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajmg.c.31552","article-title":"The 2017 international classification of the Ehlers-Danlos syndromes.","volume":"175","author":"Malfait","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2169\/internalmedicine.2983-19","article-title":"Vascular Ehlers-Danlos syndrome with a novel missense mutation in COL3A1: a man in his 50s with aortic dissection after interventional treatment for hemothorax as the first manifestation.","volume":"58","author":"Sakai","year":"2019","journal-title":"Intern Med"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O","article-title":"Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK).","volume":"77","author":"Beighton","year":"1998","journal-title":"Am J Med Genet"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/GIM.0b013e3182180c89","article-title":"COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy.","volume":"13","author":"Leistritz","year":"2011","journal-title":"Genet Med"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/ejhg.2010.105","article-title":"Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.","volume":"18","author":"Meienberg","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.33963\/KP.15005","article-title":"Vascular Ehlers-Danlos syndrome in 2 Polish patients: identification of 2 novel COL3A1 gene mutations.","volume":"77","author":"Konieczy\u0144ska","year":"2019","journal-title":"Kardiol Pol"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41436-019-0470-9","article-title":"Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility.","volume":"21","author":"Ghali","year":"2019","journal-title":"Genet Med"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/ajmg.a.38345","article-title":"Biallelic COL3A1 mutations result in a clinical spectrum of specific structural brain anomalies and connective tissue abnormalities.","volume":"173","author":"Horn","year":"2017","journal-title":"Am J Med Genet A"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ejhg.2014.181","article-title":"Vascular Ehlers-Danlos Syndrome in siblings with biallelic COL3A1 sequence variants and marked clinical variability in the extended family.","volume":"23","author":"J\u00f8rgensen","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"e001996","DOI":"10.1161\/CIRCGEN.117.001996","article-title":"Accuracy of clinical diagnostic criteria for patients with vascular Ehlers-Danlos syndrome in a tertiary referral centre.","volume":"12","author":"Henneton","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4274\/balkanmedj.2018.1113","article-title":"Updates in clinical and genetics aspects of hypermobile Ehlers Danlos Syndrome","volume":"36","author":"Forghani","year":"2019","journal-title":"Balkan Med J"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cge.13653","article-title":"Application of the 2017 criteria for vascular Ehlers-Danlos syndrome in 50 patients ascertained according to the Villefranche nosology.","volume":"97","author":"Ritelli","year":"2020","journal-title":"Clin Genet"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM200003093421001","article-title":"Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.","volume":"342","author":"Pepin","year":"2000","journal-title":"N Engl J Med"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31553","article-title":"Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome.","volume":"175","author":"Byers","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003495-199141060-00009","article-title":"Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.","volume":"41","author":"Milne","year":"1991","journal-title":"Drugs"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.jacc.2019.01.058","article-title":"Vascular Ehlers-Danlos Syndrome: long-term observational study.","volume":"73","author":"Frank","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-198206000-00001","article-title":"Doxycycline.","volume":"4","author":"Cunha","year":"1982","journal-title":"Ther Drug Monit"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function.","volume":"33","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0140-6736(10)60960-9","article-title":"Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.","volume":"376","author":"Ong","year":"2010","journal-title":"Lancet"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejvs.2020.10.020","article-title":"Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome.","volume":"61","author":"Baderkhan","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1096\/fj.11-182162","article-title":"Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts.","volume":"26","author":"M\u00fcller","year":"2012","journal-title":"FASEB J"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2133.1988.tb01745.x","article-title":"Detection of type III collagen in skin fibroblasts from patients with Ehlers-Danlos syndrome type IV by immunofluorescence.","volume":"118","author":"Temple","year":"1988","journal-title":"Br J Dermatol"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10522-015-9602-z","article-title":"Hutchinson-Gilford progeria syndrome as a model for vascular aging.","volume":"17","author":"Brassard","year":"2016","journal-title":"Biogerontology"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1073\/pnas.94.5.1852","article-title":"Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development.","volume":"94","author":"Liu","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor.","volume":"355","author":"Loeys","year":"2006","journal-title":"N Engl J Med"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1096\/fj.201900377R","article-title":"Restoring extracellular matrix synthesis in senescent stem cells.","volume":"33","author":"Rong","year":"2019","journal-title":"FASEB J"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2015.1121348","article-title":"The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells.","volume":"17","author":"Gawlik-Rzemieniewska","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(03)00392-1","article-title":"Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells.","volume":"113","author":"Chambers","year":"2003","journal-title":"Cell"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"17058","DOI":"10.1074\/jbc.M100754200","article-title":"Identification of novel TGF-beta \/Smad gene targets in dermal fibroblasts using a combined cDNA microarray\/promoter transactivation approach.","volume":"276","author":"Verrecchia","year":"2001","journal-title":"J Biol Chem"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.ymthe.2005.07.158","article-title":"618. A novel gene therapy strategy for vascular Ehlers-Danlos Syndrome by the combination with RNAi mediated inhibition of a mutant allele and transcriptional activation of a normal allele.","volume":"11","author":"Watanabe","year":"2005","journal-title":"Molecular Therapy"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl oxidase: an oxidative enzyme and effector of cell function.","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1042\/EBC20180050","article-title":"Lysyl oxidases: from enzyme activity to extracellular matrix cross-links.","volume":"63","author":"Vallet","year":"2019","journal-title":"Essays Biochem"},{"issue":"Suppl 1","key":"R47-20250619","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/IJG.0000000000000910","article-title":"Lysyl oxidases: functions and disorders.","volume":"27","author":"Rodriguez-Pascual","year":"2018","journal-title":"J Glaucoma"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"36341","DOI":"10.1074\/jbc.M003362200","article-title":"Lysyl oxidase activates the transcription activity of human collagene III promoter. Possible involvement of Ku antigen.","volume":"275","author":"Giampuzzi","year":"2000","journal-title":"J Biol Chem"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/DCR.0000000000001001","article-title":"A variant of COL3A1 (rs3134646) is associated with risk of developing diverticulosis in white men.","volume":"61","author":"Reichert","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.22170","article-title":"Identification of COL3A1 and RAB2A as novel translocation partner genes of PLAG1 in lipoblastoma.","volume":"53","author":"Yoshida","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"70508","DOI":"10.18632\/oncotarget.19733","article-title":"Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis.","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/jid.2014.455","article-title":"The Tsk2\/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene.","volume":"135","author":"Long","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-2-32","article-title":"Ehlers-Danlos syndrome type IV.","volume":"2","author":"Germain","year":"2007","journal-title":"Orphanet J Rare Dis"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:01:26Z","timestamp":1750348886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000419","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}